Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNB2 | O95067 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.41 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 10/20 | 0.40 |
| ▸ | FLT3 | P36888 | 2/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19337232 | 0.85 | CCNB2 (0.44) | CCNB2CDK1CCNB1CCNB3EGFR | |
| SCHEMBL19699869 | 0.83 | EGFR (0.51) | EGFR | |
| SCHEMBL3819496 | 0.83 | HTR6 (0.58) | FLT3HTR6CYP3A4CYP2D6 | |
| SCHEMBL19337151 | 0.82 | HTR6 (0.44) | CCNB2CDK1CCNB1CCNB3EGFR | |
| SCHEMBL17683130 | 0.79 | MKNK2 (0.49) | CCNB2CDK1CCNB1CCNB3EGFR | |
| SCHEMBL29394916 | 0.79 | MKNK2 (0.49) | CCNB2CDK1CCNB1CCNB3EGFR | |
| SCHEMBL29419125 | 0.75 | MKNK1 (0.50) | EGFRFLT3DYRK1AKDM4E | |
| SCHEMBL5096322 | 0.75 | MKNK1 (0.50) | EGFRFLT3DYRK1AKDM4E | |
| SCHEMBL17683155 | 0.73 | MKNK2 (0.43) | EGFRDYRK1AKDM4EPOLBCTDSP1 | |
| SCHEMBL30460028 | 0.73 | MKNK2 (0.43) | EGFRDYRK1AKDM4EPOLBCTDSP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208967-A1 | Pyrimidine or Pyridine Compounds, Preparation Method Therefor and Pharmaceutical Uses Thereof | INVENTISBIO CO LTD (CN) | 2024-06-27 | — | — | US | disclosed |
| US-10179784-B2 | Pyrimidine or pyridine compounds, preparation method therefor and pharmaceutical uses thereof | INVENTISBIO SHANGHAI LTD. (CN) | 2019-01-15 | — | — | US | disclosed |
| US-20170355696-A1 | PYRIMIDINE OR PYRIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | InventisBio Co., Ltd. (CN) | 2017-12-14 | — | — | US | disclosed |
| US-20170355696-A1 | PYRIMIDINE OR PYRIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | InventisBio Co., Ltd. (CN) | 2017-12-14 | — | — | US | disclosed |
| EP-3216786-A1 | PYRIMIDINE OR PYRIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | Shanghai Shaletech Technology Co., Ltd. (CN) | 2017-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208967-A1 | Pyrimidine or Pyridine Compounds, Preparation Method Therefor and Pharmaceutical Uses Thereof | EGFR, WEE1, DPYD | CCNB2 2525/4885CDK1 374/4885CCNB1 1740/4885 |
| US-20170355696-A1 | PYRIMIDINE OR PYRIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | EGFR, WEE1, DPYD | CCNB2 2802/4885CDK1 598/4885CCNB1 2168/4885 |
| US-10179784-B2 | Pyrimidine or pyridine compounds, preparation method therefor and pharmaceutical uses thereof | EGFR, WEE1, DPYD | CCNB2 2525/4885CDK1 374/4885CCNB1 1740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.